Trading Report: The Illumina Inc. (ILMN) Given a $135.00 Price Target by Canaccord Genuity Analysts

The Illumina Inc. (ILMN) Given a $135.00 Price Target by Canaccord Genuity Analysts

Illumina Inc. (NASDAQ:ILMN) has been assigned a $135.00 price target by investment analysts at Canaccord Genuity in a report released on Wednesday. The firm presently has a “hold” rating on the life sciences company’s stock. Canaccord Genuity’s price target points to a potential downside of 0.14% from the stock’s current price.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. boosted their target price on Illumina from $185.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 27th. Cantor Fitzgerald reissued a “hold” rating and issued a $165.00 target price on shares of Illumina in a research report on Wednesday, July 27th. Mizuho boosted their target price on Illumina from $138.00 to $148.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 27th. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating and set a $186.00 target price for the company in a research report on Thursday, July 28th. Finally, Argus boosted their target price on Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and a consensus target price of $152.88.

Shares of Illumina (NASDAQ:ILMN) traded up 0.57% during trading on Wednesday, reaching $135.19. 342,958 shares of the company’s stock were exchanged. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47. The firm has a market cap of $19.86 billion, a price-to-earnings ratio of 45.37 and a beta of 1.24. The stock has a 50-day moving average price of $140.46 and a 200 day moving average price of $152.80.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.10. The firm earned $607 million during the quarter, compared to analyst estimates of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. Illumina’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.80 EPS. On average, analysts forecast that Illumina will post $3.32 EPS for the current year.

In other news, Director Robert S. Epstein sold 300 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the completion of the transaction, the director now directly owns 6,924 shares in the company, valued at approximately $1,206,783.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Bradbury sold 600 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $136.34, for a total value of $81,804.00. Following the transaction, the director now owns 17,065 shares of the company’s stock, valued at $2,326,642.10. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Checchi Capital Advisers LLC increased its position in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Illumina by 1.1% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,698 shares of the life sciences company’s stock worth $467,000 after buying an additional 39 shares in the last quarter. Nippon Life Insurance Co. increased its position in Illumina by 0.5% in the second quarter. Nippon Life Insurance Co. now owns 7,877 shares of the life sciences company’s stock worth $1,106,000 after buying an additional 40 shares in the last quarter. Concert Wealth Management Inc. increased its position in Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock worth $315,000 after buying an additional 48 shares in the last quarter. Finally, Regent Investment Management LLC increased its position in Illumina by 1.8% in the second quarter. Regent Investment Management LLC now owns 4,250 shares of the life sciences company’s stock worth $597,000 after buying an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 93.52% of the company’s stock.

Illumina Company Profile

Related posts

Leave a Comment